1652 — Fusen Pharmaceutical Co Balance Sheet
0.000.00%
- HK$554.48m
- HK$870.27m
- CNY326.03m
- 16
- 42
- 32
- 16
Annual balance sheet for Fusen Pharmaceutical Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Short Term Investments | |||||
| Cash and Short Term Investments | 313 | 81.7 | 133 | 36.1 | 21.1 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 240 | 259 | 311 | 328 | 277 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 660 | 509 | 614 | 567 | 460 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 486 | 506 | 530 | 562 | 621 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 1,241 | 1,239 | 1,350 | 1,344 | 1,238 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 548 | 489 | 722 | 665 | 772 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 582 | 581 | 736 | 780 | 868 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Other Equity | |||||
| Total Equity | 659 | 658 | 614 | 564 | 370 |
| Total Liabilities & Shareholders' Equity | 1,241 | 1,239 | 1,350 | 1,344 | 1,238 |
| Total Common Shares Outstanding |